AtWork Opens New Location in Ogden Under Leadership of Local Staffing Veteran, Jason Anderson
By GlobeNewswire Published on May 20, 2025, 19:30 IST
OGDEN, Utah, May 20, 2025 (GLOBE NEWSWIRE) — AtWork ®, the nation's leading staffing franchise for empowering job seekers and facilitating company growth, has opened its newest location in Ogden, Utah, at 4872 S. 1900 W. near Riverdale Road under the ownership of local resident, Jason Anderson.
Jason Anderson is a seasoned staffing-industry professional with 30 years of experience under his belt. Jason began his career in recruiting immediately after graduating from the University of Utah and worked his way up to regional vice president for a major staffing company, overseeing locations across multiple states. Driven by the belief that staffing is one of the most rewarding industries, he has dedicated his career to supporting individuals and communities. As he takes this step into business ownership, he is grateful to share this journey with his wife, five children and six grandchildren.
'Staffing is unique because our work opens doors for people to achieve their goals,' said Jason. 'It's incredibly rewarding to make a real impact, not just for individuals, but for the entire community. With AtWork, I have the opportunity to deliver exceptional support to the businesses and job seekers in Ogden, a city I know well and have been part of for much of my life.'
For more than three decades, AtWork's mission has been to connect people with jobs and jobs with people. With more than 100 locations nationwide, AtWork puts nearly 50,000 individuals to work each year in administrative, light-industrial, accounting and finance, hospitality, IT and management-level positions at some of the nation's largest and most recognizable companies.
'We're proud to open our doors in Ogden, providing a trusted resource for job seekers and growing businesses in the area,' said Jason Leverant, President and COO of AtWork. 'AtWork Ogden will serve as a key player in helping employees thrive, businesses prosper and communities flourish. Jason is the perfect partner to champion our mission and lead with a locally owned and operated approach.'
AtWork Ogden is located at:4872 South 1900 WestRoy, UT 84067
(801) 436-6679
For more information, visit AtWork.com/ogden-ut .
###
ABOUT ATWORK:
Headquartered in Knoxville, Tennessee, AtWork is an award-winning staffing franchise with over 100 locations worldwide. Recognized by Franchise Business Review as a Top 200 Franchise; Entrepreneur® as a Top 500 and Top Franchise for Diversity, Equity and Inclusion; Franchise Times Top 400 Franchise; Staffing Industry Analyst as the Best Staffing Firms to Work for; and as Clearly Rated's Best of Staffing® for Client Satisfaction and Talent Satisfaction, AtWork can staff an entire production facility or provide temporary help around the office. For more than 30 years, leading companies from across the nation have trusted AtWork to recruit the best talent. AtWork has all of your staffing needs covered. To learn more about our services, visit AtWork.com .
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
3 hours ago
- Business Wire
Faraday Future Announces Inclusion in Russell 3000® and Russell Microcap® Indexes
LOS ANGELES--(BUSINESS WIRE)--Faraday Future Intelligent Electric Inc. ('Faraday Future' or 'FF') (NASDAQ: FFAI), a California-based global shared intelligent electric mobility ecosystem company, today announced that it has been added to both the Russell 3000® Index and the Russell Microcap® Index, effective at the open of the U.S. equity markets on June 30, 2025, as part of the 2025 annual Russell indexes reconstitution. Membership in the Russell 3000® Index, which remains in place for one year, means Faraday Future is also eligible for inclusion in either the Russell 1000® Index or Russell 2000® Index, and in this case additionally included in the Russell Microcap® Index, reflecting the Company's market capitalization positioning. These widely followed benchmarks are used by investment managers and institutional investors for index funds and as performance benchmarks, and inclusion can potentially increase investor awareness and broaden the shareholder base. 'We are honored to be included in both the Russell 3000 and Russell Microcap Indexes,' said Jerry Wang, Global President of Faraday Future. 'This inclusion highlights the momentum we are building in the intelligent electric vehicle sector and underscores our commitment to delivering innovative mobility solutions that redefine premium while affordable user experiences via Faraday Future and Faraday X - our unique dual branding strategy.' The annual reconstitution of the Russell US indexes captures the 4,000 largest US stocks as of April 30, ranking them by total market capitalization. Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $18.1 trillion in assets are benchmarked against the Russell US indexes, which belong to FTSE Russell, the global index provider. About FTSE Russell, an LSEG Business FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally. FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $18.1 trillion is benchmarked to FTSE Russell indexes. Leading asset owners, asset managers, ETF providers and investment banks choose FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives. A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering. FTSE Russell is wholly owned by London Stock Exchange Group. ABOUT FARADAY FUTURE Faraday Future is a California-based global shared intelligent electric mobility ecosystem company. Founded in 2014, the Company's mission is to disrupt the automotive industry by creating a user-centric, technology-first, and smart driving experience. Faraday Future's flagship model, the FF91, exemplifies its vision for luxury, innovation, and performance. The new FX strategy aims to introduce mass production models equipped with state-of-the-art luxury technology similar to the FF 91, targeting a broader market with middle-to-low price range offerings. FF is committed to redefining mobility through AI innovation. Join us in shaping the future of intelligent transportation. For more information, please visit
Business Upturn
4 hours ago
- Business Upturn
Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline
Long-term efficacy and safety data on PALSONIFY TM (paltusotine) in acromegaly to be presented, including evidence of both biochemical and symptom control with a well-tolerated safety profile in patients switching treatments and those not previously pharmacologically treated Atumelnant Phase 2 trial results in congenital adrenal hyperplasia (CAH) to be featured in oral presentation Data from early-stage development program in Graves' hyperthyroidism and orbitopathy also to be featured SAN DIEGO, June 30, 2025 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced eight abstracts from its novel clinical development programs, including oral presentations featuring its lead investigational drug candidate, PALSONIFY™ (paltusotine)* and investigational candidate atumelnant, will be presented at the Endocrine Society's Annual Meeting, ENDO 2025, July 12-15, 2025, in San Francisco, California. 'ENDO 2025 will be an incredibly meaningful moment for Crinetics in our mission to be the premier endocrine-focused global pharmaceutical company,' said Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics. 'For our lead investigational candidate PALSONIFY for acromegaly, we are excited to present long-term data that continue to support the durable, consistent response profile it has shown in earlier pivotal trials. Additionally, compelling Phase 2 trial results from atumelnant in CAH and new data from one of our early-stage development programs demonstrate that the Crinetics pipeline can address significant unmet needs.' Four abstracts will report results from the PALSONIFY development program, including an oral presentation featuring open-label extension data from the registrational Phase 3 PATHFNDR trials. This presentation will highlight long-term efficacy, safety, and symptom control in people with acromegaly who switched from injectable somatostatin receptor ligands (SRLs) to once-daily oral PALSONIFY. In addition, Crinetics will present three poster presentations: one evaluating symptom stability in acromegaly, one analyzing patient-reported outcomes from both PATHFNDR-1 and PATHFNDR-2 and another on PATHFNDR-2 open-label extension data. Together, these abstracts show PALSONIFY continues to be well tolerated, while providing consistent biochemical and symptomatic disease control. Crinetics will also present three abstracts from its atumelnant clinical development program, including an oral presentation of Phase 2 trial results in congenital adrenal hyperplasia (CAH). Additional presentations focus on reduction of adrenal volume and rapid and sustained reductions in potent 11-oxygenated androgens, a novel biomarker, in Phase 2 trial participants. Beyond its two lead programs, Crinetics will present new data from its early-stage pipeline, including data from CRN12755 for Graves' hyperthyroidism and orbitopathy. Additional presentation details are shown below. All times are PT: *The U.S. Food and Drug Administration recently conditionally approved PALSONIFY as the trade name for paltusotine, our once-daily, oral investigational candidate for acromegaly. PALSONIFY™ (paltusotine) Presentations Title: Paltusotine Results in Improved Symptom Stability in Biochemically Controlled Acromegaly Authors: David Clemmons, MD et. al. Date/Time: July 13, 12:00-1:30 PM Location: Session P34 – Neuroendocrinology and Pituitary: Acromegaly, Prolactinoma, Other Functioning Pituitary Tumors (Except Cushing) II – ENDOExpo Poster Area: SUN-043 Title: Effects of Paltusotine Treatment on Patient-Reported Symptoms of Acromegaly in Phase 3 Randomized Placebo-Controlled Studies (PATHFNDR-2 and PATHFNDR-1) Authors: Avery A. Rizio, PhD et. al. Date/Time: July 13, 12:00-1:30 PM Location: Session P34 – Neuroendocrinology and Pituitary: Acromegaly, Prolactinoma, Other Functioning Pituitary Tumors (Except Cushing) II – ENDOExpo Poster Area: SUN-052 Title: Disease Control in Patients With Acromegaly Switching From Injected Somatostatin Receptor Ligands to Once-Daily Oral Paltusotine: Interim Results of the PATHFNDR-1 Open-Label Extension Authors: Beverly M. K. Biller, MD et. al. Date/Time: July 13, 2:45-3:00 PM Location: Session OR12-07 – Neuroendocrinology and Pituitary: Management of Pituitary Disorders – Room 201 Title: Once-Daily Oral Paltusotine in the Treatment of Patients With Biochemically Uncontrolled Acromegaly: Interim Results of the PATHFNDR-2 Open-Label Extension Authors: Monica R. Gadelha, MD, PhD et. al. Date/Time: July 14, 12:00–1:30 PM Location: Session P77 – Neuroendocrinology and Pituitary: Acromegaly, Prolactinoma, Other Functioning Pituitary Tumors (except Cushing) III – ENDOExpo: Poster Area; MON-069 Atumelnant Presentations Title: Reductions in Adrenal Volume in Patients With Congenital Adrenal Hyperplasia Receiving Once-Daily Oral Atumelnant (CRN04894): Interim Results From a 12-Week, Phase 2, Open-Label Study Authors: Tania A.S.S. Bachega, MD, PhD et. al. Date/Time: July 12, 12:15-1:45 PM Location: Session P18 – Adrenal (Excluding Mineralocorticoids): Adrenal Insufficiency and CAH I – ENDOExpo Poster Area: SAT-452 Title: Once-Daily Oral Atumelnant (CRN04894) Induces Rapid, Substantial, and Sustained Reductions of Androstenedione and 17‑Hydroxyprogesterone in Adults With Classical Congenital Adrenal Hyperplasia: Interim Results From a 12-Week, Phase 2, Open-Label Study Authors: Umasuthan Srirangalingam, MD, PhD et. al. Date/Time: July 12, 2:30-2:45 PM Location: Session OR07-06 – Adrenal (Excluding Mineralocorticoids): All About Congenital Adrenal Hyperplasia and Adrenal Insufficiency – Room 204 Title: -Rapid and Sustained Reduction of 11-Oxygenated Androgens in Adults With Classic Congenital Adrenal Hyperplasia Following Once-Daily Oral Atumelnant (CRN04894): Results From a 12-Week, Phase 2, Open-Label Study Authors: Nicole Reisch, MD et. al. Date/Time: July 13, 12:00-1:30 PM Location: Session P55 – Adrenal (Excluding Mineralocorticoids): Adrenal Insufficiency and CAH II – ENDOExpo Poster Area: SUN-438 Early-Stage Pipeline Presentations Title: Discovery and Characterization of an Orally Bioavailable Nonpeptide Thyroid Stimulating Hormone Receptor (TSHR) Antagonist for the Treatment of Graves' Disease and Thyroid Eye Disease Authors: Eulalia A. Coutinho, PhD et. al. Date/Time: July 14, 12:00-1:30 PM Location: Session P92 – Thyroid Biology and Disease: Benign Thyroid Disorders (Auto-Immune) II – ENDOExpo Poster Area: MON-365 Crinetics Sponsored Science & Innovation Theaters Title: Optimizing Long-Term Control in Acromegaly: Key to Improved Patient Outcomes Presenters: Shlomo Melmed, MB ChB; Christian J. Strasburger, MD Date/Time: July 14, 9:30 AM-10:30 AM Location: Theater 1 Title: Navigating the Complexities & Challenges of Acromegaly Management Presenters: Lisa B. Nachtigall, MD; Laurence Katznelson, MD; Scott Struthers, PhD Date/Time: July 14, 12:30 PM -1:30 PM Location: Theater 1 About PALSONIFY™ (Paltusotine) Crinetics' lead development candidate, PALSONIFY, is the first investigational once-daily, oral, selectively-targeted somatostatin receptor type 2 (SST2) nonpeptide agonist that has completed Phase 3 clinical development for acromegaly and is in Phase 3 clinical development for carcinoid syndrome associated with neuroendocrine tumors. It was designed to be a once-daily oral option for the control of acromegaly and carcinoid syndrome. In Phase 3 studies, once-daily, oral PALSONIFY maintained IGF-1 levels and symptom control in patients with acromegaly who were switched from monthly injectable medications (PATHFNDR-1) and rapidly decreased IGF-1 levels and symptom burden in medically untreated acromegaly patients (PATHFNDR-2). IGF-1 is the primary biomarker endocrinologists use to manage acromegaly patients. Results from a Phase 2 study in carcinoid syndrome demonstrated rapid and sustained reductions in flushing episodes and bowel movement frequency, which are the most common symptoms of carcinoid syndrome, leading to the initiation of a Phase 3 trial for control of carcinoid syndrome in patients with neuroendocrine tumors. About Atumelnant Atumelnant, Crinetics' second investigational compound, is the first once-daily, oral adrenocorticotropic hormone (ACTH) receptor antagonist that acts selectively at the melanocortin type 2 receptor (MC2R) on the adrenal gland. Diseases associated with excess ACTH can have significant impact on physical and mental health. Atumelnant has exhibited strong binding affinity for MC2R in preclinical models and has demonstrated suppression of adrenally derived glucocorticoids and androgens that are under the control of ACTH. Data from a 12-week Phase 2 study demonstrated compelling treatment benefits of atumelnant, evidenced by the rapid, substantial and sustained statistically significant reductions in key CAH disease related biomarkers, including androstenedione and 17-hydroxyprogesterone, in a diverse population. Atumelnant is in development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, with the Phase 3 CALM-CAH trial and a Phase 1/2b trial in ADCS currently enrolling patients. About Crinetics Pharmaceuticals Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics' lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome. All of the company's drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding the plans and timelines for the clinical development of atumelnant and paltusotine, including the therapeutic potential and clinical benefits or safety profile thereof; the plans and timelines for the commercial launch PALSONIFY if approved; the potential clinical benefits of our TSHR antagonist, CRN12755, in patients across multiple indications, and the anticipated timing of clinical trials, registration applications or the therapeutic potential for our development candidates. In some cases, you can identify forward-looking statements by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplates,' 'believes,' 'estimates,' 'predicts,' 'potential,' 'upcoming' or 'continue' or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including, without limitation, initial or topline data that we report may change following completion or a more comprehensive review of the data related to the clinical studies and such data may not accurately reflect the complete results of a clinical study, and the FDA and other regulatory authorities may not agree with our interpretation of such results; geopolitical events may disrupt Crinetics' business and that of the third parties on which it depends, including delaying or otherwise disrupting its clinical studies and preclinical studies, manufacturing and supply chain, or impairing employee productivity; the success of Crinetics' clinical studies and nonclinical studies; regulatory developments in the United States and foreign countries; clinical studies and preclinical studies may not proceed at the time or in the manner expected, or at all; the timing and outcome of research, development and regulatory review is uncertain, and Crinetics' drug candidates may not advance in development or be approved for marketing; and the other risks and uncertainties described in the Company's periodic filings with the Securities and Exchange Commission (SEC). The events and circumstances reflected in the company's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Additional information on risks facing Crinetics can be found under the heading 'Risk Factors' in Crinetics' periodic filings with the SEC, including its annual report on Form 10-K for the year ended December 31, 2024 and quarterly report on Form 10-Q for the quarter ended March 31, 2025. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by applicable law, Crinetics does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contact: Media: Natalie Badillo Head of Corporate Communications [email protected] (858) 345-6075
Business Upturn
4 hours ago
- Business Upturn
ETHRANSACTION Launches the New Gold Standard in Dogecoin Mining
London, UK, June 30, 2025 (GLOBE NEWSWIRE) — The crypto world is back in the spotlight. With Bitcoin surging past $110,000 and Dogecoin gaining steam due to expanding 'X Money' ambitions and ETF buzz, the stage is set for another volatile ride. Market experts see DOGE climbing another 17% this month alone. But with every climb, sharp drops often follow—sometimes as steep as 20% in a single day. While many scramble to time the markets, smart investors are turning to a more stable solution: cloud mining. And at the front of this new wave is ETHRANSACTION, a platform designed to deliver daily, predictable earnings, even when the market swings wildly. No Hardware, No Stress — Just Earnings Founded in 2017, ETHRANSACTION offers a rare blend of security, profitability, and green mining. Forget expensive GPUs and constant maintenance. With ETHRANSACTION: No hardware purchase required No technical knowledge needed Daily fixed income regardless of price swings Dogecoin, Bitcoin, Ethereum, XRP — mine them all flexibly Users simply register, activate a mining plan, and start earning. Your earnings show up daily, consistent, anti-volatility income in the midst of market chaos. Smart Contract Mining — Starting at Just $19 ETHRANSACTION makes mining accessible to all, with no upfront cost to test the waters. Every new user receives a $19 trial bonus upon sign-up. This can be used immediately to activate a trial contract. From there, choose from tailored investment tiers: Contract Price Duration Daily Income Total at Maturity Total Profit $100 2 days $9 $118 $18 $600 5 days $7.5 $637.5 $37.5 $1300 15 days $16.9 $1553.5 $253.5 $33000 40 days $610.5 $57420 $24420 Whether you're a cautious beginner or an aggressive investor, there's a contract built for you. Withdraw profits anytime or reinvest them for compounding rewards. Triple-Layer Security & Green Mining ETHRANSACTION puts user security and sustainability at the core of its mission: Insurance Coverage: Contracts insured by Legal & General — your capital is protected. Contracts insured by Legal & General — your capital is protected. Bank-Grade Encryption: EV SSL, McAfee® anti-hack protocols, and cold wallet storage. EV SSL, McAfee® anti-hack protocols, and cold wallet storage. Eco-Certified Mining: 100% of ETHRANSACTION's global mining network runs on wind and solar power. Each mined DOGE saves approximately 0.3kg in carbon emissions. New June 2025 Event: 'X Cloud Surge Campaign' To celebrate the surge in DOGE and ETH, ETHRANSACTION is launching a limited-time bonus event — 'X Cloud Surge Campaign'. From June 30 to July 15, all new users will receive: An extra $10 bonus on top of the regular $19 registration gift on top of the regular $19 registration gift 5% boost on all contract earnings during the campaign on all contract earnings during the campaign Double referral commissions for inviting friends This exclusive campaign is the perfect chance to maximize passive earnings while DOGE and ETH dominate headlines. Lock In Pre-Halving Profits — Don't Wait Dogecoin's next halving event is expected to slash miner rewards in the coming months. This means less earnings for more effort — unless you act now. Contracts purchased today lock in today's high returns before those cuts kick in. More than 8 million users globally have already joined ETHRANSACTION, generating consistent, round-the-clock income while others gamble with market timing. While traders chase pumps and panic at dips, ETHRANSACTION users sleep easy knowing their crypto is working for them, day and night. Ready to Start? Here's How: Visit the official site: Register and claim your $19 free bonus Select your first mining contract Watch Dogecoin and other assets earn passively Withdraw or reinvest profits — your call This is more than a trend — it's a movement toward smarter, sustainable crypto earnings. Skip the stress, skip the guesswork. ETHRANSACTION delivers daily wealth automatically. Official Site: Customer Support: [email protected] Disclaimer: The information provided in this press release does not constitute an investment solicitation, nor does it constitute investment advice, financial advice, or trading recommendations. Cryptocurrency mining and staking involve risks and the possibility of losing funds. It is strongly recommended that you perform due diligence before investing or trading in cryptocurrencies and securities, including consulting a professional financial advisor. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
